Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation

References

• Giralt S A, Arora M, Goldman J M, Lee S J, Maziarz R T, McCarthy P L, et al. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. Br J Haematol 2007; 137: 461–467
   PubMed Web of Science ®Google Scholar
• Gratwohl A, Schmid O, Baldomero H, Horisberger B, Urbano-Ispizua A. Haematopoietic stem cell transplantation (HSCT) in Europe 2002. Changes in indication and impact of team density. A report of the EBMT activity survey. Bone Marrow Transplant 2004; 34: 855–875
   PubMed Web of Science ®Google Scholar
• Bornhauser M, Kroger N, Schwerdtfeger R, Schafer-Eckart K, Sayer H G, Scheid C, et al. Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study. Eur J Haematol 2006; 76: 9–17
   PubMed Web of Science ®Google Scholar
• Myojo T, Hino N. Complete remission from chronic myelogenous leukemia – blastic crisis caused by reduced intensity stem cell transplantation following partial remission due to imatinib. Intern Med 2004; 43: 126–130
   PubMed Web of Science ®Google Scholar
• Chen M H, Chiou T J, Lin P C, Gau J P, Hsu H C, Hsiao L T, et al. Comparison of myeloablative and nonmyeloablative hematopoietic stem cell transplantation for treatment of chronic myeloid leukemia. Int J Hematol 2007; 86: 275–281
   PubMed Web of Science ®Google Scholar
• Kebriaei P, Saliba R M, Ma C, Ippoliti C, Couriel D R, de L M, et al. Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia. Bone Marrow Transplant 2006; 38: 203–209
   PubMed Web of Science ®Google Scholar
• Frame D. Chronic myeloid leukemia: standard treatment options. Am J Health Syst Pharm 2006; 63(23 Suppl. 8)S10–S14
   Google Scholar
• Kujawski L, Talpaz M. Strategies for overcoming imatinib resistance in chronic myeloid leukemia. Leuk Lymphoma 2007; 48: 2310–2322
   PubMed Web of Science ®Google Scholar
• Martinez C, Gomez V, Tomas J F, Parody R, Sureda A, Sanz G, et al. Relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: outcome and prognostic factors: the Chronic Myeloid Leukemia Subcommittee of the GETH (Grupo Espanol de Trasplante Hemopoyetico). Bone Marrow Transplant 2005; 36: 301–306
   PubMed Web of Science ®Google Scholar
• Bekassy A N, Hermans J, Gorin N C, Gratwohl A. Granulocytic sarcoma after allogeneic bone marrow transplantation: a retrospective European multicenter survey. Acute and Chronic Leukemia Working Parties of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1996; 17: 801–808
   PubMed Web of Science ®Google Scholar
• Koc Y, Miller K B, Schenkein D P, Daoust P, Sprague K, Berkman E. Extramedullary tumors of myeloid blasts in adults as a pattern of relapse following allogeneic bone marrow transplantation. Cancer 1999; 85: 608–615
   PubMed Web of Science ®Google Scholar
• Rossetti J M, Lister J, Shadduck R K, Bloom E, Geyer S J, Caushaj P F, et al. Localized lymphoid relapse in the pancreas following allogeneic hematopoietic stem cell transplant for chronic myelogenous leukemia. Leuk Lymphoma 2003; 44: 1071–1074
   PubMed Web of Science ®Google Scholar
• Ustun C, Arslan O, Beksac M, Koc H, Gurman G, Ozcelik T, et al. A retrospective comparison of allogeneic peripheral blood stem cell and bone marrow transplantation results from a single center: a focus on the incidence of graft-vs.-host disease and relapse. Biol Blood Marrow Transplant 1999; 5: 28–35
   PubMedGoogle Scholar
• Byrd J C, Weiss R B. Recurrent granulocytic sarcoma. An unusual variation of acute myelogenous leukemia associated with 8;21 chromosomal translocation and blast expression of the neural cell adhesion molecule. Cancer 1994; 73: 2107–2112
   PubMed Web of Science ®Google Scholar
• Park J, Park S Y, Cho H I, Lee D. Isolated extramedullary relapse in the pleural fluid of a patient with acute myeloid leukemia following allogeneic BMT. Bone Marrow Transplant 2002; 30: 57–59
   PubMed Web of Science ®Google Scholar
• Paydas S, Zorludemir S, Ergin M. Granulocytic sarcoma: 32 cases and review of the literature. Leuk Lymphoma 2006; 47: 2527–2541
   PubMed Web of Science ®Google Scholar
• Owonikoko T, Agha M, Balassanian R, Smith R, Raptis A. Gemtuzumab therapy for isolated extramedullary AML relapse following allogeneic stem-cell transplant. Nat Clin Pract Oncol 2007; 4: 491–495
   PubMedGoogle Scholar
• Cunningham I. A clinical review of breast involvement in acute leukemia. Leuk Lymphoma 2006; 47: 2517–2526
   PubMed Web of Science ®Google Scholar
• Guglielmi C, Arcese W, Dazzi F, Brand R, Bunjes D, Verdonck L F, et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood 2002; 100: 397–405
   PubMed Web of Science ®Google Scholar
• Kolb H J, Schattenberg A, Goldman J M, Hertenstein B, Jacobsen N, Arcese W, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041–2050
   PubMed Web of Science ®Google Scholar
• Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108: 28–37
   PubMed Web of Science ®Google Scholar
• Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108: 1809–1820
   PubMed Web of Science ®Google Scholar
• Alizadeh M, Bernard M, Danic B, Dauriac C, Birebent B, Lapart C, et al. Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction. Blood 2002; 99: 4618–4625
   PubMed Web of Science ®Google Scholar
• Fehse B, Chukhlovin A, Kuhlcke K, Marinetz O, Vorwig O, Renges H, et al. Real-time quantitative Y chromosome-specific PCR (QYCS-PCR) for monitoring hematopoietic chimerism after sex-mismatched allogeneic stem cell transplantation. J Hematother Stem Cell Res 2001; 10: 419–425
   PubMedGoogle Scholar
• Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D, et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006; 108: 1092–1099
   PubMed Web of Science ®Google Scholar
• Martel L, Reddy K, Greco M, Tuscano M, Richman M, Wun T. Isolated cavernous sinus extramedullary relapse of chronic myelogenous leukemia following allogeneic stem cell transplant. Ann Hematol 2002; 81: 108–110
   PubMed Web of Science ®Google Scholar
• Hu S W, Huang S P, Yang S F, Chai C Y. Chloroma of the testis after allogeneic peripheral blood stem cell transplantation: a case report. Kaohsiung J Med Sci 2004; 20: 506–511
   PubMedGoogle Scholar
• Kroschinsky F, Friedrich K, Hanel M, Mohr B, Langer T, Meinhardt M, et al. Extramedullary blast crisis of chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation mimicking aggressive, translocation t(14;18)-positive B-cell lymphoma. Ann Hematol 2003; 82: 47–52
   PubMed Web of Science ®Google Scholar
• Au W Y, Chan A C, Lie A K, So J C, Liang R, Kwong Y L. Isolated extramedullary relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant 1998; 22: 99–102
   PubMed Web of Science ®Google Scholar
• Lee J J, Kim H J, Kook H, Chung I J, Seo J S, Seo K S, et al. Granulocytic sarcoma as isolated extramedullary relapse after donor lymphocyte infusion in a patient with CML who relapsed after allogeneic bone marrow transplantation: a case report. J Korean Med Sci 1998; 13: 434–436
   PubMedGoogle Scholar
• Fritz J, Vogel W, Bares R, Horger M. Radiologic spectrum of extramedullary relapse of myelogenous leukemia in adults. AJR Am J Roentgenol 2007; 189: 209–218
   PubMed Web of Science ®Google Scholar
• Zent C, Rowley J D, Nucifora G. Rearrangements of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: in vitro and in vivo studies. Leukemia 1997; 11(Suppl. 3)273–278
   PubMedGoogle Scholar
• Weisberg E, Manley P W, Cowan-Jacob S W, Hochhaus A, Griffin J D. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007; 7: 345–356
   PubMed Web of Science ®Google Scholar
• Aichberger K J, Herndlhofer S, Agis H, Sperr W R, Esterbauer H, Rabitsch W, et al. Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy. Eur J Clin Invest 2007; 37: 808–813
   PubMed Web of Science ®Google Scholar
• Altintas A, Cil T, Kilinc I, Kaplan M A, Ayyildiz O. Central nervous system blastic crisis in chronic myeloid leukemia on imatinib mesylate therapy: a case report. J Neurooncol 2007; 84: 103–105
   PubMed Web of Science ®Google Scholar
• Petzer A L, Gunsilius E, Hayes M, Stockhammer G, Duba H C, Schneller F, et al. Low concentrations of STI571 in the cerebrospinal fluid: a case report. Br J Haematol 2002; 117: 623–625
   PubMed Web of Science ®Google Scholar
• Takayama N, Sato N, O'Brien S G, Ikeda Y, Okamoto S. Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. Br J Haematol 2002; 119: 106–108
   PubMed Web of Science ®Google Scholar
• Abruzzese E, Del P G, Barbato R, Fratoni S, Trawinska M M, Zangrilli D, et al. Complete regression of cutaneous lesions of refractory Ph+ ALL after 4 weeks of treatment with BMS-354825. Blood 2006; 107: 4571–4572
   PubMed Web of Science ®Google Scholar
• Breccia M, Nanni M, Mancini F, Russo E, Mecarocci S, Alimena G. Extramedullary blast crisis occurring in a Philadelphia-positive chronic myeloid leukemia patient with major cytogenetic response to imatinib. Haematologica 2004; 89: ECR11
   Google Scholar
• Porkka K, Koskenvesa P, Lundan T, Rimpilainen J, Mustjoki S, Smykla R, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 2008; 112: 1005–1012
   PubMed Web of Science ®Google Scholar
• Slevin M L, Piall E M, Aherne G W, Johnston A, Lister T A. The pharmacokinetics of cytosine arabinoside in the plasma and cerebrospinal fluid during conventional and high-dose therapy. Med Pediatr Oncol 1982; 10(Suppl. 1)157–168
   PubMedGoogle Scholar